Table 2 The average levels of the participants characteristics after one year of treatment

Vitamin D (75–250 nmol/L)

62.2 (± 6.2)

56 (± 7.1)

0.15^a

Calcium (2.2–2.5 mmol/L)

2.30 (± 0.15)

2.33 (± 0.16)

0.67^a

Phosphorous (0.8–1.5 mmol/L)

1.19 (± 0.14)

1.17 (± 0.19)

0.69^a

Serum creatinine (40–115 µmol/L)

107.3 (± 25.5)

109.2 (± 26.3)

0.68^a

Urea (2.5–6.4 mmol/L)

6.1 (± 2.3)

5.55 (± 2.62)

0.18^a

Sodium (135–145 mmol/L)

138.52 (± 3.4)

138.7 (± 3.9)

0.69^a

Chloride (98–107 mmol/L)

103.5 (± 3.1)

103.6 (± 3.31)

0.79^a

Uric acid (208–425 µmol/L)

343.81 (± 75)

351.68 (± 69)

0.31^a

Reported side effects

 Injection site reaction

10 (20%)

0

–

 Stomach upset

0

11 (22.9%)

0.001^b

 Abdominal pain

8 (15.4%)

9 (18.75%)

0.65^a

 Diarrhea and vomiting

5 (9.6%)

15 (31.25%)

0.006^b

 Hypocalcaemia

6 (11.5%)

1 (2.1%)

0.037^b

 Fractures

0

0

–

 Acute rejection

0

0

–